1. Japan Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Nxera Pharma Co., Ltd.

Nxera Pharma Co., Ltd.

4565.T
Nxera Pharma Co., Ltd.JP flagTokyo Stock Exchange
972.00
JPY
+2.00
- -
89.16BMarket Cap

Total Valuation

Nxera Pharma Co., Ltd. carries a market capitalization of 89.16B, placing it among publicly traded companies globally. Its enterprise value stands at 159.80B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap89.16B
Enterprise Value159.80B

Share Statistics

Nxera Pharma Co., Ltd. currently has 89.90M shares outstanding.

Shares Outstanding89.90M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 5.99, and the price-to-book ratio stands at 5.30.

PE RatioN/A
PS Ratio5.99
PB Ratio5.30
P/TBV Ratio-14.90
P/FCF Ratio-3,676.48
P/OCF Ratio-178.65

Enterprise Valuation

EV / Sales6.85
EV / EBITDAN/A
EV / EBITN/A
EV / FCF62.47

Financial Position

Nxera Pharma Co., Ltd. maintains a current ratio of 4.11, meaning it holds 4.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 103.04, indicating elevated leverage, while an interest coverage ratio of -3.39 demonstrates limited ability to service its debt obligations.

Current Ratio4.11
Quick Ratio3.29
Debt / Equity103.04
Debt / EBITDA-7.89
Interest Coverage-3.39

Financial Efficiency

Return on Equity (ROE)-34.41
Return on Assets (ROA)-7.55
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover5.50

Taxes

Income Tax-242.00M
Effective Tax RateN/A

Stock Price Statistics

Nxera Pharma Co., Ltd.'s stock has gained approximately 13.68421% over the past 52 weeks. The 50-day moving average sits at 1,026.92, while the 200-day moving average is 930.94.

Beta (5Y)N/A
52-Week Price Change13.68421%
50-Day Moving Average1,026.92
200-Day Moving Average930.94
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Nxera Pharma Co., Ltd. generated 23.34B in revenue and converted that into -9.84B in net income, yielding earnings per share of -112.86. EBITDA reached -9.01B, while operating income came in at -9.01B.

Revenue23.34B
Gross Profit16.97B
Operating Income-9.01B
Pretax Income-10.08B
Net Income-9.84B
EBITDA-9.01B
EBIT-9.01B
Earnings Per Share (EPS)-112.86

Balance Sheet

Nxera Pharma Co., Ltd. holds 50.98B in cash and equivalents against 71.07B in total debt, resulting in a net debt position of 15.29B. Total book value stands at 26.37B, with working capital of 48.14B providing operational flexibility.

Cash & Cash Equivalents50.98B
Total Debt71.07B
Net Debt15.29B
Equity (Book Value)26.37B
Book Value Per Share302.51
Working Capital48.14B

Cash Flow

Nxera Pharma Co., Ltd. produced -782.00M in operating cash flow over the past twelve months. After subtracting -744.00M in capital expenditures, free cash flow totaled -1.53B - equivalent to -17.51 per share.

Operating Cash Flow-782.00M
Capital Expenditures-744.00M
Free Cash Flow-1.53B
FCF Per Share-17.51

Margins

Nxera Pharma Co., Ltd. operates with a gross margin of 72.71, reflecting its pricing power and cost economics. The operating margin of -38.61 and net profit margin of -42.14 provide insight into operational efficiency.

Gross Margin72.71
Operating Margin-38.61
Pretax Margin-43.18
Profit Margin-42.14
EBITDA Margin-38.61

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-32.17
FCF Yield-0.03

Stock Splits

Nxera Pharma Co., Ltd.'s most recent stock split took place on June 27, 2018 with a 1:4 split ratio.

Last Split Date6/27/2018
Split Ratio1:4

Scores

Nxera Pharma Co., Ltd. posts an Altman Z-Score of 1.24, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.24